Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2025-04-24 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of a company regarding the approval of various reports including the 2024 Annual Report, 2024 Financial Statements, 2025 Q1 Report, Profit Distribution Plan, and Internal Control Self-Evaluation Report. It references that the actual reports are published separately on the cninfo website with specific announcement numbers. The document itself is short (2045 characters) and does not contain the full financial data or detailed report content but rather the meeting resolutions and approvals. This fits the pattern of a Regulatory Filing (RNS) as it is an official announcement of meeting resolutions and approvals related to reports, not the reports themselves. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2025-04-24 Chinese
关于公司股票交易被实施退市风险警示暨停牌的公告
Delisting Announcement Classification · 100% confidence The document is an official announcement from the company regarding the implementation of a delisting risk warning and suspension of stock trading due to poor financial performance in the 2024 fiscal year. It references the audited annual report but does not contain the report itself. The document details the reasons for the risk warning, regulatory rules, and potential delisting risks, which aligns with a delisting announcement. The document length is short (2228 characters), and it is clearly an announcement about stock trading status and risk warnings, not a full financial report or audit report. Therefore, the appropriate classification is Delisting Announcement (DLST).
2025-04-24 Chinese
监事会关于公司计提减值准备事项合理性的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the supervisory board (监事会) of 赛隆药业集团股份有限公司 regarding the reasonableness of the company's impairment provision for the year 2024. It references compliance with accounting standards and stock exchange listing rules, and confirms the adequacy and legality of the impairment provision. The document is short (392 characters) and serves as an explanatory note or certification rather than a full financial report or audit report. It does not contain detailed financial data or audit results but rather a supervisory board's confirmation. This fits best under Regulatory Filings (RNS) as it is a regulatory compliance-related announcement that does not fit other specific categories like Audit Report or Annual Report.
2025-04-24 Chinese
2024年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度董事会工作报告" which translates to "2024 Annual Board of Directors Work Report." It details the activities, meetings, and decisions of the board of directors throughout the year 2024, including summaries of financial performance, board meeting attendance, resolutions passed, and governance activities. It does not contain full financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it focuses on the board's work and governance activities over the year. This aligns with the category of Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management. The document length is 3775 characters, which is sufficient for a detailed board report but not a full annual report. Therefore, the best classification is MANG with high confidence.
2025-04-24 Chinese
2024独立董事述职报告（潘传云）
Board/Management Information Classification · 95% confidence The document is titled as an independent director's annual performance report for the year 2024. It details the director's attendance at board and shareholder meetings, participation in committees, communication with auditors, and oversight activities related to financial reports and internal controls. The content focuses on the director's duties and activities during the year rather than presenting financial statements or audit results themselves. The document length is 3535 characters, which is relatively short and consistent with a report or statement rather than a full financial report. This type of document is best classified as Board/Management Information (MANG), as it relates to management and board-level reporting on governance and oversight activities rather than a full annual report or audit report.
2025-04-24 Chinese
年度股东大会通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of shareholders for 赛隆药业集团股份有限公司. It includes information about the meeting date, location, voting procedures (including online voting), agenda items to be discussed and voted on, and instructions for shareholders on how to participate. The document does not contain financial statements or detailed financial performance data but rather focuses on the logistics and agenda of the AGM. It also includes attachments such as proxy forms and voting instructions. The document length is under 5,000 characters, and it is clearly a meeting notice rather than the actual report or results of the meeting. Therefore, it fits the category of AGM Information (AGM-R).
2025-04-24 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.